Apellis Pharmaceuticals, Inc. (APLS) scores 55 out of 100 on boothcheck's 11-model valuation framework. Verdict: Fair The estimated fair value is 25.9, representing a 36% premium to fair value. Quantitative score: 53/100. Qualitative score: 80/100.
Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.